

# Stephen Hart

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1559068/publications.pdf>

Version: 2024-02-01

114  
papers

4,422  
citations

101496

36  
h-index

114418

63  
g-index

116  
all docs

116  
docs citations

116  
times ranked

4468  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lipid-peptide nanocomplexes for mRNA delivery in vitro and in vivo. <i>Journal of Controlled Release</i> , 2022, 348, 786-797.	4.8	16
2	Assembly strategy of liposome and polymer systems for siRNA delivery. <i>International Journal of Pharmaceutics</i> , 2021, 592, 120033.	2.6	32
3	CRISPR/Cas9 gene editing therapies for cystic fibrosis. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1-14.	1.4	9
4	Higher throughput drug screening for rare respiratory diseases: Readthrough therapy in primary ciliary dyskinesia. <i>European Respiratory Journal</i> , 2021, 58, 2000455.	3.1	13
5	Integrin-Targeted, Short Interfering RNA Nanocomplexes for Neuroblastoma Tumor-Specific Delivery Achieve <i>MYCN</i> Silencing with Improved Survival. <i>Advanced Functional Materials</i> , 2021, 31, 2104843.	7.8	12
6	Allele-Specific Small Interfering RNA Corrects Aberrant Cellular Phenotype in Keratitis-Ichthyosis-Deafness Syndrome Keratinocytes. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1035-1044.e7.	0.3	18
7	Liposomal delivery of hydrophobic RAMBAs provides good bioavailability and significant enhancement of retinoic acid signalling in neuroblastoma tumour cells. <i>Journal of Drug Targeting</i> , 2020, 28, 643-654.	2.1	4
8	The liposomal delivery of hydrophobic oxidovanadium complexes imparts highly effective cytotoxicity and differentiating capacity in neuroblastoma tumour cells. <i>Scientific Reports</i> , 2020, 10, 16660.	1.6	7
9	Toward gene therapy in rheumatoid arthritis. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 123-133.	0.4	4
10	New approaches to genetic therapies for cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2020, 19, S54-S59.	0.3	46
11	Silencing E3 Ubiquitin ligase ITCH as a potential therapy to enhance chemotherapy efficacy in p53 mutant neuroblastoma cells. <i>Scientific Reports</i> , 2020, 10, 1046.	1.6	11
12	<i>MYCN</i> Silencing by RNAi Induces Neurogenesis and Suppresses Proliferation in Models of Neuroblastoma with Resistance to Retinoic Acid. <i>Nucleic Acid Therapeutics</i> , 2020, 30, 237-248.	2.0	9
13	The discovery and enhanced properties of trichain lipids in lipopolyplex gene delivery systems. <i>Organic and Biomolecular Chemistry</i> , 2019, 17, 945-957.	1.5	8
14	A Nanosensor Toolbox for Rapid, Label-Free Measurement of Airway Surface Liquid and Epithelial Cell Function. <i>ACS Applied Materials &amp; Interfaces</i> , 2019, 11, 8731-8739.	4.0	6
15	Targeted suicide gene transfections reveal promising results in nu/nu mice with aggressive neuroblastoma. <i>Journal of Controlled Release</i> , 2018, 275, 208-216.	4.8	12
16	A beginner's guide to gene editing. <i>Experimental Physiology</i> , 2018, 103, 439-448.	0.9	12
17	Development of Targeted siRNA Nanocomplexes to Prevent Fibrosis in Experimental Glaucoma Filtration Surgery. <i>Molecular Therapy</i> , 2018, 26, 2812-2822.	3.7	36
18	Gene editing and gene regulation with CRISPR. <i>Experimental Physiology</i> , 2018, 103, 437-438.	0.9	3

#	ARTICLE	IF	CITATIONS
19	Effective silencing of ENaC by siRNA delivered with epithelial-targeted nanocomplexes in human cystic fibrosis cells and in mouse lung. <i>Thorax</i> , 2018, 73, 847-856.	2.7	50
20	Peptide and nucleic acid-directed self-assembly of cationic nanovehicles through giant unilamellar vesicle modification: Targetable nanocomplexes for in vivo nucleic acid delivery. <i>Acta Biomaterialia</i> , 2017, 51, 351-362.	4.1	28
21	BMI-1 extends proliferative potential of human bronchial epithelial cells while retaining their mucociliary differentiation capacity. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2017, 312, L258-L267.	1.3	40
22	Delivery of ENaC siRNA to epithelial cells mediated by a targeted nanocomplex: a therapeutic strategy for cystic fibrosis. <i>Scientific Reports</i> , 2017, 7, 700.	1.6	51
23	Prospects for RNA delivery with nanotechnologies. <i>Gene Therapy</i> , 2017, 24, 121-121.	2.3	2
24	Genotype-Phenotype Associations of <i>IL6</i> and <i>PRG4</i> With Conjunctival Fibrosis After Glaucoma Surgery. <i>JAMA Ophthalmology</i> , 2017, 135, 1147.	1.4	13
25	Genome-wide RNA-Sequencing analysis identifies a distinct fibrosis gene signature in the conjunctiva after glaucoma surgery. <i>Scientific Reports</i> , 2017, 7, 5644.	1.6	16
26	Genetic therapies for cystic fibrosis lung disease. <i>Current Opinion in Pharmacology</i> , 2017, 34, 119-124.	1.7	27
27	23. SiRNA and CRISPR/Cas9 Mediated Knockout of ENaC. <i>Molecular Therapy</i> , 2016, 24, S11.	3.7	0
28	588. MYCN Silencing Using RNA Interference Causes Apoptosis and Differentiation in MYCN Amplified Neuroblastoma Cell Lines. <i>Molecular Therapy</i> , 2016, 24, S233.	3.7	0
29	Systematic Comparisons of Formulations of Linear Oligolysine Peptides with siRNA and Plasmid DNA. <i>Chemical Biology and Drug Design</i> , 2016, 87, 747-763.	1.5	24
30	A critical role for ATF2 transcription factor in the regulation of E-selectin expression in response to non-endotoxin components of <i>Neisseria meningitidis</i> . <i>Cellular Microbiology</i> , 2016, 18, 66-79.	1.1	5
31	Receptor-targeted liposome-peptide-siRNA nanoparticles represent an efficient delivery system for MRTF silencing in conjunctival fibrosis. <i>Scientific Reports</i> , 2016, 6, 21881.	1.6	44
32	Minicircle DNA Provides Enhanced and Prolonged Transgene Expression Following Airway Gene Transfer. <i>Scientific Reports</i> , 2016, 6, 23125.	1.6	50
33	155. Lipid-Peptide Receptor-Targeted siRNA Nanoparticles for Systemic Delivery To Tumours. <i>Molecular Therapy</i> , 2015, 23, S62.	3.7	0
34	A method for concentrating lipid peptide DNA and siRNA nanocomplexes that retains their structure and transfection efficiency. <i>International Journal of Nanomedicine</i> , 2015, 10, 2673.	3.3	13
35	Role of liposome and peptide in the synergistic enhancement of transfection with a lipopolyplex vector. <i>Scientific Reports</i> , 2015, 5, 9292.	1.6	34
36	Improved intracellular delivery of peptide- and lipid-nanoplexes by natural glycosides. <i>Journal of Controlled Release</i> , 2015, 206, 75-90.	4.8	25

#	ARTICLE	IF	CITATIONS
37	Receptor-targeted liposome-peptide-siRNA nanoparticles represent a novel and efficient siRNA delivery system to prevent conjunctival fibrosis. <i>Acta Ophthalmologica</i> , 2015, 93, n/a-n/a.	0.6	0
38	Combined exome and whole-genome sequencing identifies mutations in <i>ARMC4</i> as a cause of primary ciliary dyskinesia with defects in the outer dynein arm. <i>Journal of Medical Genetics</i> , 2014, 51, 61-67.	1.5	88
39	PEGylation improves the receptor-mediated transfection efficiency of peptide-targeted, self-assembling, anionic nanocomplexes. <i>Journal of Controlled Release</i> , 2014, 174, 177-187.	4.8	47
40	Multifunctional, self-assembling anionic peptide-lipid nanocomplexes for targeted siRNA delivery. <i>Biomaterials</i> , 2014, 35, 8406-8415.	5.7	64
41	The Role of the Helper Lipid on the DNA Transfection Efficiency of Lipopolyplex Formulations. <i>Scientific Reports</i> , 2014, 4, 7107.	1.6	145
42	Multifunctional receptor-targeted nanocomplexes for the delivery of therapeutic nucleic acids to the Brain. <i>Biomaterials</i> , 2013, 34, 9190-9200.	5.7	49
43	Gene Delivery Using Ternary Lipopolyplexes Incorporating Branched Cationic Peptides: The Role of Peptide Sequence and Branching. <i>Molecular Pharmaceutics</i> , 2013, 10, 127-141.	2.3	29
44	Comparison of Nanocomplexes with Branched and Linear Peptides for siRNA Delivery. <i>Biomacromolecules</i> , 2013, 14, 761-770.	2.6	23
45	Airway Deposition of Nebulized Gene Delivery Nanocomplexes Monitored by Radioimaging Agents. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2013, 49, 471-480.	1.4	15
46	Inhibition of neointimal hyperplasia in a rabbit vein graft model following non-viral transfection with human iNOS cDNA. <i>Gene Therapy</i> , 2013, 20, 979-986.	2.3	20
47	Multifunctional receptor-targeted nanocomplexes for magnetic resonance imaging and transfection of tumours. <i>Biomaterials</i> , 2012, 33, 7241-7250.	5.7	25
48	Lipid peptide nanocomplexes for gene delivery and magnetic resonance imaging in the brain. <i>Journal of Controlled Release</i> , 2012, 162, 340-348.	4.8	32
49	Elemental imaging of MRI contrast agents: benchmarking of LA-ICP-MS to MRI. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 403, 1641-1649.	1.9	25
50	Lipid chain geometry of C14 glycerol-based lipids: effect on lipoplex structure and transfection. <i>Molecular BioSystems</i> , 2011, 7, 422-436.	2.9	8
51	Integrin-targeted nanocomplexes for tumour specific delivery and therapy by systemic administration. <i>Biomaterials</i> , 2011, 32, 1370-1376.	5.7	53
52	Receptor-targeted liposome-peptide nanocomplexes for siRNA delivery. <i>Biomaterials</i> , 2011, 32, 6302-6315.	5.7	76
53	Comparative structural and functional studies of nanoparticle formulations for DNA and siRNA delivery. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2011, 7, 210-219.	1.7	114
54	Nebulisation of Receptor-Targeted Nanocomplexes for Gene Delivery to the Airway Epithelium. <i>PLoS ONE</i> , 2011, 6, e26768.	1.1	35

#	ARTICLE	IF	CITATIONS
55	Multifunctional nanocomplexes for gene transfer and gene therapy. <i>Cell Biology and Toxicology</i> , 2010, 26, 69-81.	2.4	64
56	Tumor-specific gene transfer with receptor-mediated nanocomplexes modified by polyethylene glycol shielding and endosomally cleavable lipid and peptide linkers. <i>FASEB Journal</i> , 2010, 24, 2301-2313.	0.2	52
57	Stabilized Integrin-Targeting Ternary LPD (Lipopolyplex) Vectors for Gene Delivery Designed To Disassemble Within the Target Cell. <i>Bioconjugate Chemistry</i> , 2009, 20, 518-532.	1.8	39
58	Synthesis of Bifunctional Integrin-Binding Peptides Containing PEG Spacers of Defined Length for Non-Viral Gene Delivery. <i>European Journal of Organic Chemistry</i> , 2008, 2008, 2900-2914.	1.2	13
59	Mono- and dicationic short PEG and methylene dioxyalkylglycerols for use in synthetic gene delivery systems. <i>Organic and Biomolecular Chemistry</i> , 2008, 6, 2554.	1.5	20
60	Acid cleavable PEG-lipids for applications in a ternary gene delivery vector. <i>Molecular BioSystems</i> , 2008, 4, 532.	2.9	27
61	A Receptor-targeted Nanocomplex Vector System Optimized for Respiratory Gene Transfer. <i>Molecular Therapy</i> , 2008, 16, 907-915.	3.7	59
62	Receptor-targeted Nanocomplexes optimized for Gene Transfer to Primary Vascular Cells and Explant Cultures of Rabbit Aorta. <i>Molecular Therapy</i> , 2008, 16, 508-515.	3.7	23
63	Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12. <i>British Journal of Cancer</i> , 2007, 97, 210-217.	2.9	33
64	Biophysical Characterization of an Integrin-Targeted Lipopolyplex Gene Delivery Vector. <i>Biochemistry</i> , 2007, 46, 12930-12944.	1.2	33
65	Targeting Lipopolyplexes Using Bifunctional Peptides Incorporating Hydrophobic Spacer Amino Acids: Synthesis, Transfection, and Biophysical Studies. <i>Bioconjugate Chemistry</i> , 2007, 18, 1800-1810.	1.8	14
66	Analysis and Optimization of the Cationic Lipid Component of a Lipid/Peptide Vector Formulation for Enhanced Transfection In Vitro and In Vivo. <i>Journal of Liposome Research</i> , 2006, 16, 373-389.	1.5	22
67	Application to Vascular Adventitia of a Nonviral Vector for TIMP-1 Gene Therapy to Prevent Intimal Hyperplasia. <i>Human Gene Therapy</i> , 2006, 17, 717-727.	1.4	15
68	540. Genetic Intervention towards Improving the Long Term Outcome of CABG Using a Lipid Peptide DNA Vector System. <i>Molecular Therapy</i> , 2006, 13, S207-S208.	3.7	0
69	696. Development of Lipid/Peptide (Lip/Tide) Vectors for Respiratory Gene Transfer. <i>Molecular Therapy</i> , 2006, 13, S269-S270.	3.7	0
70	1080. Receptor-Targeting Smart Vectors for Efficient Gene Transfer to Tumours. <i>Molecular Therapy</i> , 2006, 13, S414.	3.7	0
71	Calcineurin regulates NFAT-dependent iNOS expression and protection of cardiomyocytes: Co-operation with Src tyrosine kinase. <i>Cardiovascular Research</i> , 2006, 71, 672-683.	1.8	43
72	Application to Vascular Adventitia of a Nonviral Vector for TIMP-1 Gene Therapy to Prevent Intimal Hyperplasia. <i>Human Gene Therapy</i> , 2006, .	1.4	0

#	ARTICLE	IF	CITATIONS
73	Efficient Gene Transfer by Lipid/Peptide Transfection Complexes. , 2006, , 293-316.		0
74	The fractal structure of polycationâ€“DNA complexes. Biotechnology and Applied Biochemistry, 2005, 41, 127.	1.4	8
75	Lipid Carriers for Gene Therapy. Current Drug Delivery, 2005, 2, 423-428.	0.8	54
76	Transbronchial biopsies provide longitudinal evidence for epithelial chimerism in children following sex mismatched lung transplantation. Thorax, 2005, 60, 60-62.	2.7	60
77	Rate of transport of L-arginine is independent of the expression of inducible nitric oxide synthase in HEK 293 cells. Nitric Oxide - Biology and Chemistry, 2005, 12, 21-30.	1.2	5
78	Targeted Gene Delivery to Human Airway Epithelial Cells with Synthetic Vectors Incorporating Novel Targeting Peptides Selected by Phage Display. Journal of Drug Targeting, 2004, 12, 185-193.	2.1	49
79	Efficient transfection of non-proliferating human airway epithelial cells with a synthetic vector system. Journal of Gene Medicine, 2004, 6, 210-221.	1.4	26
80	Severity of Lung Injury in Cyclooxygenase-2-Deficient Mice Is Dependent on Reduced Prostaglandin E2 Production. American Journal of Pathology, 2004, 165, 1663-1676.	1.9	111
81	Functional delivery of large genomic DNA to human cells with a peptide-lipid vector. Journal of Gene Medicine, 2003, 5, 883-892.	1.4	29
82	Formation of LID vector complexes in water alters physicochemical properties and enhances pulmonary gene expression in vivo. Gene Therapy, 2003, 10, 1026-1034.	2.3	27
83	Enhancement of integrin-mediated transfection of haematopoietic cells with a synthetic vector system. Biotechnology and Applied Biochemistry, 2003, 38, 201.	1.4	10
84	Prediction of size distribution of lipidâ€“peptideâ€“DNA vector particles using Monte Carlo simulation techniques. Biotechnology and Applied Biochemistry, 2003, 38, 95.	1.4	7
85	Improved antitumour immunity in murine neuroblastoma using a combination of IL-2 and IL-12. British Journal of Cancer, 2003, 88, 1641-1648.	2.9	33
86	Large Animal Models: Bridging the Gap. Molecular Therapy, 2003, 8, 528-529.	3.7	2
87	Biophysical characterization of an integrin-targeted non-viral vector. Medical Science Monitor, 2003, 9, BR54-61.	0.5	8
88	Cyclooxygenase-2 Overexpression, Using an Integrin-Targeted Gene Delivery System (the LID Vector), Inhibits Fibroblast Proliferation In Vitro and Leads to Increased Prostaglandin E2 in the Lung. Chest, 2002, 121, 102S-104S.	0.4	13
89	High efficiency transfection of porcine vascular cells in vitro with a synthetic vector system. Journal of Gene Medicine, 2002, 4, 292-299.	1.4	26
90	Evaluation of a porcine model for pulmonary gene transfer using a novel synthetic vector. Journal of Gene Medicine, 2002, 4, 438-446.	1.4	44

#	ARTICLE	IF	CITATIONS
91	Effective gene transfer to solid tumors using different nonviral gene delivery techniques: Electroporation, liposomes, and integrin-targeted vector. <i>Cancer Gene Therapy</i> , 2002, 9, 399-406.	2.2	98
92	Cyclooxygenase-2 Deficiency Results in a Loss of the Anti-Proliferative Response to Transforming Growth Factor- $\beta$ in Human Fibrotic Lung Fibroblasts and Promotes Bleomycin-Induced Pulmonary Fibrosis in Mice. <i>American Journal of Pathology</i> , 2001, 158, 1411-1422.	1.9	236
93	In vivo myocardial gene transfer: Optimization, evaluation and direct comparison of gene transfer vectors. <i>Basic Research in Cardiology</i> , 2001, 96, 227-236.	2.5	86
94	Non-viral, integrin-mediated gene transfer into fibroblasts from patients with lysosomal storage diseases. <i>Journal of Gene Medicine</i> , 2001, 3, 488-497.	1.4	10
95	An integrin-targeted non-viral vector for pulmonary gene therapy. <i>Gene Therapy</i> , 2000, 7, 393-400.	2.3	85
96	Stable integration of large (>100 kb) PAC constructs in HaCaT keratinocytes using an integrin-targeting peptide delivery system. <i>Gene Therapy</i> , 2000, 7, 1600-1605.	2.3	34
97	Adhesion molecules and gene transfer. <i>Advanced Drug Delivery Reviews</i> , 2000, 44, 135-152.	6.6	30
98	Synthetic vectors for gene therapy. <i>Expert Opinion on Therapeutic Patents</i> , 2000, 10, 199-208.	2.4	11
99	Gene delivery to hypoxic cells in vitro. <i>British Journal of Cancer</i> , 2000, 83, 662-667.	2.9	21
100	Use of Adhesion Molecules for Gene Delivery. <i>Nephron Experimental Nephrology</i> , 1999, 7, 193-199.	2.4	11
101	High-Titer Recombinant Adeno-Associated Virus Production from Replicating Amplicons and Herpes Vectors Deleted for Glycoprotein H. <i>Human Gene Therapy</i> , 1999, 10, 2527-2537.	1.4	47
102	Integrin-mediated vectors for gene transfer and therapy. <i>Current Opinion in Molecular Therapeutics</i> , 1999, 1, 197-203.	2.8	7
103	An RGD-Oligolysine Peptide: A Prototype Construct for Integrin-Mediated Gene Delivery. <i>Human Gene Therapy</i> , 1998, 9, 1037-1047.	1.4	184
104	Lipid-Mediated Enhancement of Transfection by a Nonviral Integrin-Targeting Vector. <i>Human Gene Therapy</i> , 1998, 9, 575-585.	1.4	183
105	Recombinant HMG1 Protein Produced in <i>Pichia pastoris</i> : A Nonviral Gene Delivery Agent. <i>BioTechniques</i> , 1997, 22, 718-729.	0.8	48
106	Integrin-mediated transfection with peptides containing arginine-glycine-aspartic acid domains. <i>Gene Therapy</i> , 1997, 4, 1225-1230.	2.3	97
107	High Yield Incorporation of Plasmid DNA within Liposomes: Effect on DNA Integrity and Transfection Efficiency. <i>Journal of Drug Targeting</i> , 1996, 3, 469-475.	2.1	65
108	Integrin-Mediated Gene Delivery. , 1996, , 101-106.		0

#	ARTICLE	IF	CITATIONS
109	Efficient Incorporation of Plasmid DNA Within Liposomes of Varying Structural Characteristics: Liposomal DNA Integrity and Transfection Efficiency. , 1996, , 143-150.		0
110	The introduction of two silent mutations into a CFTR cDNA construct allows improved detection of exogenous mRNA in gene transfer experiments. Human Molecular Genetics, 1995, 4, 1597-1602.	1.4	6
111	Gene delivery and expression mediated by an integrin-binding peptide. Gene Therapy, 1995, 2, 552-4.	2.3	115
112	Cell binding and internalization by filamentous phage displaying a cyclic Arg-Gly-Asp-containing peptide. Journal of Biological Chemistry, 1994, 269, 12468-74.	1.6	122
113	Noninvasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nature Genetics, 1993, 5, 135-142.	9.4	425
114	Effective gene transfer to solid tumors using different nonviral gene delivery techniques: Electroporation, liposomes, and integrin-targeted vector. , 0, .		1